Logo wahanariau.com
  2. Boehringer ingelheim

Boehringer ingelheim

Index
Globenewswire

JASCAYD® (nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China

Kamis, 11 Desember 2025 - 00:35:41 Wib
Globenewswire

Boehringer Ingelheim announces appointment to Board of Managing Directors

Sabtu, 29 November 2025 - 02:47:07 Wib
Globenewswire

Boehringer Ingelheim Obtains two EU CVMP Positive Opinions for Avian Influenza Vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5

Jumat, 21 November 2025 - 03:27:51 Wib
Globenewswire

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

Rabu, 05 November 2025 - 03:00:28 Wib
Globenewswire

Boehringer Ingelheim Acquires License from Kyowa Kirin Aimed at Developing a Novel Treatment for Patients with Autoimmune Diseases

Kamis, 30 Oktober 2025 - 22:02:26 Wib
Globenewswire

JASCAYD® (nerandomilast) Approved in China for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Jumat, 24 Oktober 2025 - 01:15:45 Wib
Globenewswire

Boehringer’s Zongertinib Demonstrated a 77% Objective Response Rate in Treatment-naïve Patients with Advanced HER2 (ERBB2)-mutant NSCLC

Sabtu, 18 Oktober 2025 - 04:31:45 Wib
Globenewswire

Boehringer Ingelheim Advances Cancer Antibody-drug Conjugate Portfolio with Asset from AimedBio

Rabu, 15 Oktober 2025 - 21:23:58 Wib
Globenewswire

U.S. FDA Approves Boehringer’s JASCAYD® (nerandomilast tablets) as First New Treatment Option for Adults with IPF in Over a Decade

Jumat, 10 Oktober 2025 - 03:05:59 Wib
Globenewswire

Pooled Data Presented at ERS: Nerandomilast Monotherapy Linked to Nominally Significant Reduction in Risk of Death in IPF and PPF

Selasa, 30 September 2025 - 11:03:31 Wib
Globenewswire

Boehringer’s HERNEXEOS® Approved in China as First Oral Targeted Therapy for Previously Treated Patients with HER2-mutant Advanced NSCLC

Senin, 01 September 2025 - 22:42:33 Wib
Globenewswire

Boehringer Ingelheim and Palatin Technologies to Develop Potential First-in-class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases

Selasa, 19 Agustus 2025 - 20:07:57 Wib
Globenewswire

Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia

Jumat, 08 Agustus 2025 - 01:13:46 Wib
Globenewswire

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

Selasa, 29 Juli 2025 - 03:31:09 Wib
Globenewswire

First Half of 2025: Solid Growth, Investments and Pipeline Progress Pave the Way for Two Key Launches in H2

Kamis, 24 Juli 2025 - 21:27:34 Wib
Globenewswire

Boehringer Ingelheim Initiates Phase II Study of BI 1815368, a Potential First-in-class Oral Treatment for Diabetic Macular Edema

Senin, 07 Juli 2025 - 21:29:54 Wib
Globenewswire

Boehringer Ingelheim and Eko Health Inc. Enter Digital Health Collaboration to Improve Heart Murmur Detection in Dogs

Selasa, 10 Juni 2025 - 17:30:00 Wib
Globenewswire

Boehringer Ingelheim to Present Early Clinical Evidence of Innate Immune Modulation and Anti-tumor Activity Via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

Jumat, 23 Mei 2025 - 21:38:35 Wib
Globenewswire

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Rabu, 21 Mei 2025 - 02:57:23 Wib
Globenewswire

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-class Oral Compound as a Treatment for Geographic Atropy

Selasa, 06 Mei 2025 - 21:58:37 Wib
Globenewswire

Breaking New Ground in Mental Health Research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience Launch First of its Kind Study Investigating the Day-to-day Experience of Patients with Psychiatric Disorders

Rabu, 30 April 2025 - 03:29:13 Wib
Globenewswire

Boehringer’s New Zongertinib Data Demonstrate Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-mutant Advanced NSCLC

Selasa, 29 April 2025 - 03:09:24 Wib
Globenewswire

New Survey Shows that Over 90% of Animal Owners Trust and Appreciate Veterinary Teams but Underestimate the Demands of the Profession

Kamis, 24 April 2025 - 21:33:32 Wib
Globenewswire

Boehringer Ingelheim and Tessellate Bio Partner to Develop First-in-class Precision Treatments for People with Hard-to-treat Cancers

Rabu, 23 April 2025 - 21:18:32 Wib
Globenewswire

Boehringer Ingelheim Announces Succession Chairmen Shareholders’ Committee and Board of Managing Directors

Kamis, 17 April 2025 - 23:31:28 Wib